NYSE:MTNB
Matinas Biopharma Holdings Inc Stock News
$0.188
-0.0023 (-1.21%)
At Close: Apr 19, 2024
Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2022 Financial and Operational Results on May 12, 2022
07:00am, Thursday, 05'th May 2022
BEDMINSTER, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of n
Matinas BioPharma to Present at the 12th Annual BioNJ BioPartnering Conference
07:00am, Tuesday, 03'rd May 2022
BEDMINSTER, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids an
Thinking of Buying BioNTech? Consider These 3 Things First
02:45pm, Friday, 29'th Apr 2022 The Motley Fool
There's trouble ahead, but a few new solutions are on the way too.
HC Wainwright Reiterates Buy Rating On BioNTech, While Lowers Price Target
06:55pm, Tuesday, 12'th Apr 2022 Benzinga
HC Wainwright has reiterated its Buy rating on BioNTech SE (NASDAQ: BNTX) while reducing the price target to $298 from the prior $339.
The analyst noted initial data of BNT211, an autologous CAR-
Matinas (MTNB) Up on Deal With BioNTech for mRNA Vaccines
06:51pm, Tuesday, 12'th Apr 2022 Zacks Investment Research
Matinas BioPharma (MTNB) forms an exclusive partnership with BioNTech (BNTX) to develop and advance novel formulations for mRNA vaccines.
Matinas BioPharma Inks mRNA-Based Vaccine Pact With BioNTech
11:54am, Monday, 11'th Apr 2022
BioNTech SE (NASDAQ: BNTX) and Matinas BioPharma Holdings Inc (NYSE: MTNB) have entered into an exclusive research collaboration to evaluate the combination of mRNA formats and Matinas' proprieta
Matinas BioPharma to Present at the Needham Virtual Healthcare Conference
07:00am, Wednesday, 06'th Apr 2022
BEDMINSTER, N.J., April 06, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids
Matinas BioPharma to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
11:00am, Tuesday, 22'nd Mar 2022 GlobeNewswire Inc.
BEDMINSTER, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acid
Matinas Biopharma Holdings, Inc. (MTNB) Loses 29.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
02:00pm, Wednesday, 16'th Mar 2022 Zacks Investment Research
Matinas Biopharma Holdings, Inc. (MTNB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Stre
Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerome Jabbour on Q4 2021 Results - Earnings Call Transcript
04:13pm, Tuesday, 08'th Mar 2022 Seeking Alpha
The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout
01:00pm, Tuesday, 08'th Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative Options For Infectious Diseas
Matinas Biopharma GAAP EPS of -$0.03 beats by $0.01
11:33am, Tuesday, 08'th Mar 2022 Seeking Alpha
Matinas Biopharma press release (MTNB): Q4 GAAP EPS of -$0.03 beats by $0.01.Cash, cash equivalents and marketable securities at December 31, 2021, were approximately $49.6…
Matinas BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
11:30am, Tuesday, 08'th Mar 2022 GlobeNewswire Inc.
– Fifteen Patients Enrolled to Date in Cohort 4 of EnACT (all oral induction regimen); Topline Interim Data Expected Q3 2022 –
Matinas BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
11:30am, Tuesday, 08'th Mar 2022 GlobeNewswire
– Fifteen Patients Enrolled to Date in Cohort 4 of EnACT (all oral induction regimen); Topline Interim Data Expected Q3 2022 –
Matinas Biopharma Q4 2021 Earnings Preview
04:39pm, Monday, 07'th Mar 2022 Seeking Alpha
Matinas Biopharma (NYSE:MTNB) is scheduled to announce Q4 earnings results on Tuesday, March 8th, before market open.The consensus EPS Estimate is -$0.03 (flat Y/Y) and the…
